- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Here's a concise summary for Hikal Ltd.:
**1. Business Performance:**
Hikal's Q1 FY26 saw consolidated revenue at Rs. 380 Cr and EBITDA at Rs. 25 Cr, a slower-than-expected start. The Pharma segment generated Rs. 203 Cr, with EBIT at -12.9%, impacted by temporary hold on off-take following a US FDA Official Action Indicated (OAI) status. Crop Protection revenue was Rs. 178 Cr, flat YoY, due to global overcapacity and pricing pressure. The company reported a consolidated Net Loss of (23) Cr and EPS of (1.84).
**2. Growth Drivers or Strategy:**
Hikal is addressing FDA observations by onboarding a remediation partner and engaging regulatory authorities, implementing a comprehensive CAPA plan. They are expanding capabilities in high-potency and complex chemistry for Pharma CDMO, and several Animal Health molecules are in development for future commercialization. Focus remains on cost discipline and diversification into Personal Care and Specialty Chemicals.
**3. Recent Developments:**
Following the US FDA OAI communication, Hikal successfully completed GMP audits at its Bangalore API facility by ANVISA (Brazil) and PMDA (Japan), reinforcing its regulatory standing.
**4. Key Financial Metrics:**
Consolidated Revenue decreased 6.5% YoY, EBITDA plunged 57.4% YoY, and Net Profit saw a significant decline from 5 Cr to (23) Cr YoY.
**5. Management Commentary / Outlook:**
Management expects Pharma supplies to partially resume in Q2 and recover fully later in the year, reaffirming full FY guidance. They anticipate gradual volume recovery and stable pricing in Crop Protection by H2. The company is confident of delivering FY26 guidance, projecting a stronger recovery in Q3 and Q4, driven by increased demand visibility and new product commercialization.